Holen Sie sich die Stockscreener-App
4.955
2.84%
-0.145
Scisparc Ltd Aktie (SPRC) Neueste Nachrichten
Scisparc Ltd (SPRC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial - TipRanks
Tourette drug cut tics 21% in study as SciSparc (SPRC) advances trials - Stock Titan
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - marketscreener.com
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - The Manila Times
26 children have joined SciSparc’s two-compound autism treatment trial - Stock Titan
Neurothera Labs Inc. Announces Share Consolidation - TradingView
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com South Africa
SciSparc appoints AI professor to advisory board - Investing.com
Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026 - marketscreener.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionIV Crush Alert - vinanet.vn
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com Canada
SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind - Stock Titan
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc Ltd. (SPRC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement - NewMediaWire
NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
SciSparc Ltd. (SPRC) stock price, news, quote and history - Yahoo Finance UK
SciSparc Subsidiary NeuroThera Wins Japanese Patent for Novel Pain and Fever Therapy - TipRanks
SciSparc Ltd. (Nasdaq: SPRC) subsidiary gains Japanese patent on novel pain treatment combo - Stock Titan
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - The Manila Times
SciSparc Subsidiary NeuroThera Receives Japanese Patent for 4-Aminophenol Combination Therapy - Quiver Quantitative
Japanese patent covers SciSparc subsidiary’s pain and fever combo - Stock Titan
NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - TradingView
SPRC Stock Price, Quote & Chart - ChartMill
SciSparc (SPRC) Slips 0.87% to $6.87 as Biotech Stock Holds Above Key SupportTrend Continuation Trade - dars.gov.et
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Stock News Today - TradingKey
SciSparc’s NeuroThera Launches Phase IIb Tourette Trial at Yale Child Study Center - TipRanks
SciSparc (Nasdaq: SPRC) launches Phase IIb SCI-110 Tourette study - Stock Titan
SciSparc’s NeuroThera Opens Yale Site for Phase IIb SCI-110 Tourette Syndrome Trial - Quiver Quantitative
Tourette drug candidate enters Phase IIb with prior 21% tic reduction - Stock Titan
NeuroThera launches Phase IIb trial of SCI-110 for Tourette Syndrome at Yale Child Study Center - Pluang
Price to book forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Slips Slightly as Shares Test Key Support Near $7.11Weak Sell Signals - vinanet.vn
SciSparc (SPRC) Plunges 18.16% — Support at $6.76 Becomes CriticalRegression Channel - vinanet.vn
SciSparc Announces NeuroThera Labs Achieves Milestone in Quantum-Enabled Clinical Trial Data Analytics Platform - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics - The Manila Times
SciSparc (SPRC) Drops 4.29% as Shares Test Key Support Near $8.26Retail Sentiment - dars.gov.et
Enterprise value to EBIT forward of SciSparc Ltd. – NASDAQ:SPRC - TradingView
SciSparc (SPRC) Surges Over 70%: Analyzing the Massive RallyHigh Volume Stocks - dars.gov.et
SciSparc Moves Into Agentic AI With New Scientific Advisory Board - TipRanks
Scisparc Ltd. Announces Establishment of Scientific Advisory Board - marketscreener.com
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum - GlobeNewswire
NeuroThera Labs validates quantum platform for advanced clinical data analysis using S&P 500 hybrid computing. - Pluang
Scisparc Ltd (SPRC) Earnings Date & Reports & Earnings News - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):